Archives: Funding

  • The EIC-Accelerator project has been completed successfully

    The EIC-Accelerator project has been completed successfully

    Cardiovascular diseases (CVDs) and cancer are the first two causes of death globally, taking 27.4 M lives a year, representing 49% of all deaths worldwide. The primary cause of cardiovascular disease is atherosclerosis– the narrowing and eventual blockage of arteries by the deposition of fatty plaques in the walls of arteries. Eventually, these plaques can generate thrombosis which occludes blood flow causing stroke and heart attacks as the leading causes of death in developing countries. In the EU alone, there are about 1.2 M strokes annually. Thus, the diagnosis and treatment of cardiovascular and oncological disorders are of great importance and a key objective of the health care systems worldwide. A 40-year-old imaging technique called Digital Subtraction Angiography is widely used in the diagnosis and treatment CVDs. DSA technology has limitations and drawbacks, e.g.: image quality is often insufficient, high radiation exposure affects patients and medical staff, and the applied iodinated contrast media can lead to major kidney damage. To solve these limitations in the angiography field, Kinepict Health Ltd. has developed the ground-breaking Kinepict Medical Imaging Tool (KMIT) platform with the imaging technology called Digital Variance Angiography (DVA).

    The overall objective of the KMIT-ACC project (grant agreement No 968430) was to revolutionize X-ray angiography by introducing a dose management and image processing tool based on KMIT with the following objectives:

    a) clinical validation of our technology for new indications

    b) organization of a reference laboratory network

    c) software and hardware optimization to reach the TRL 8 level by the end of the grant period

    d) baseline commercial activities.

    Work performed: Software and hardware optimization was performed in the first phase of the project and the new imaging tool was tested during clinical validation. Clinical aims were fully achieved as the clinical data provide evidence for 1) improved image quality in novel indication areas including prostatic artery embolization and transarterial chemoembolization of liver tumors, 2) radiation dose reduction capability in lower limb angiography and prostatic artery embolization, 3) contrast agent dose reduction capability in carotid angiography. The clinical results related to this project have been published in peer-reviewed, open-access scientific journals. Based on the feedback of the clinical studies the KMIT software was upgraded and reached TRL 8.

    The project also supported the organization of the reference laboratory. The commercial backbone of KMIT's marketability has been also established. Kinepict knows the market where it wants to reach success. In addition, KMIT has the regulatory approval to enter the market. The results of the project were communicated and disseminated throughout the execution phase.

    At the end of the project, we have a unique imaging tool in our hands that is ready to be marketed and can revolutionize x-ray angiography. Kinepict Medical Imaging Tool will provide great benefits for patients and for medical professionals across the European Union and around the world. This result would have not been achieved without the EIC-Accelerator Grant.

  • Ongoing Clinical Studies Validate the Effectiveness of DVA technology

    Ongoing Clinical Studies Validate the Effectiveness of DVA technology

    In medical technology, innovation is a driving force that continually shapes the landscape of patient care and treatment. One such groundbreaking advancement is the Kinepict Medical Imaging Tool, a cutting-edge solution that has the potential to transform how medical imaging is conducted. Three ongoing clinical studies are currently underway to validate the efficacy of Kinepict across various aspects of medical imaging, showcasing its potential to revolutionize healthcare.

    1. Clinical Validation of Kinepict Medical Imaging Tool in Prostatic Artery Embolization

    Prostatic Artery Embolization (PAE) is a minimally invasive procedure used to treat benign prostatic hyperplasia, a common condition in aging men. Imaging plays a critical role in guiding this procedure, ensuring precision and successful outcomes. The ongoing clinical study aims to validate the use of the Kinepict Medical Imaging Tool in PAE.

    Early results are promising, with the Kinepict Tool providing high-resolution images that enhance the visualization of the prostate and surrounding arteries. This heightened clarity aids physicians in accurately identifying the target areas for embolization, thereby improving the overall efficacy of the procedure.

    2. Clinical Validation of the Dose Management Capabilities of Kinepict Medical Imaging Tool: Radiation Exposure Reduction

    Radiation exposure is a concern in medical imaging, particularly in procedures that require repeated imaging sessions. The second ongoing clinical study revolves around assessing the dose management capabilities of the Kinepict Tool, specifically focusing on reducing radiation exposure during imaging.

    Preliminary findings indicate that the Kinepict Tool excels in optimizing radiation doses without compromising image quality. This breakthrough could lead to a significant reduction in radiation-related risks for patients and healthcare providers. Additionally, the study underscores the potential economic benefits of reduced radiation exposure, as it could result in decreased healthcare costs associated with managing radiation-induced complications.

    3. Clinical Validation of the Dose Management Capabilities of Kinepict Medical Imaging Tool: Iodinated Contrast Material Reduction

    Iodinated contrast materials are commonly used in medical imaging procedures to enhance the visibility of certain anatomical structures. However, some patients may experience adverse reactions to these materials. The third ongoing clinical study aims to validate the Kinepict Tool's ability to manage iodinated contrast material doses effectively.

    Preliminary results suggest that the Kinepict Tool's sophisticated algorithms can minimize the required amount of iodinated contrast material while maintaining image quality. This advancement not only reduces the risk of adverse reactions but also contributes to the overall sustainability of healthcare by decreasing the demand for contrast materials. As a result, patients with allergies or sensitivities to iodine can benefit from safer imaging procedures.

    In conclusion, the ongoing clinical studies involving the Kinepict Medical Imaging Tool are poised to revolutionize medical imaging practices across various domains. The initial results from these studies highlight the potential of Kinepict to enhance the accuracy, safety, and efficiency of medical procedures. As the studies continue to unfold positively, the medical world edges closer to a new era of imaging excellence, benefitting both patients and practitioners alike.

  • Press Release: Closing of the Gyorsítósáv project

    Press Release: Closing of the Gyorsítósáv project

    Kinepict's Gyorsítósáv project has successfully finished and closed.

    Minimally invasive endovascular interventions are playing an increasingly important role in modern healthcare systems, as they are less risky and burdensome and significantly shorten the time patients spend in hospital. They are widely used in the treatment of cardiovascular diseases, cancers, and other tissue proliferation conditions (myoma, prostate enlargement), which are leading causes of death. The interventions require angiographic studies to assess the condition and the effectiveness of the intervention.

    Kinepict Health Ltd. has developed a new image processing technology, Digital Variance Angiography (DVA), which outperforms the imaging method used in minimally invasive endovascular procedures, called Digital Subtraction Angiography, in many areas by producing higher quality angiographic images with significantly better signal-to-noise ratios. In the Gyorsítósáv project, supported by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, a new color-coded parametric image and software module was developed based on DVA technology, available as part of the Kinepict Medical Imaging Tool software package. The technology has been clinically validated and provides quantitative analysis of blood flow parameters, providing significant real-time decision support to interventional radiologists. The developed software module has been named ccDVA Analysis Tool (color-coded DVA analysis tool).

    Endovascular interventions can be basically divided into two groups. These are called restorative interventions and embolization procedures. In both cases, there is a change (increase or decrease) in blood flow compared to the pre-intervention state, and the effectiveness of the therapeutic procedure depends on the degree of change. This can often be judged only by subsequent symptoms and, if ineffective, may require further intervention. Using the software module developed, the evaluated blood flow parameters can be used to decide at the operating table whether the intervention was effective enough or whether the procedure should be continued. This avoids the need for a repeat intervention at a later stage, thus saving considerable costs and improving patients' quality of life.

    2020-1.1.5-GYORSÍTÓSÁV-2021-00018 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the 2020-1.1.5-GYORSÍTÓSÁV funding scheme.  

  • Conference presentations about the clinical results of the Gyorsítósáv project

    Conference presentations about the clinical results of the Gyorsítósáv project

    The clinical team of Kinepict has evaluated the clinical data obtained from the clinical trials of the Gyorsítósáv project. The results were presented during the following scientific conferences:

    1.    Góg I et al. retrospective comparison of color-coded DVA and Siemens iFlow – pilot study. Poster presentation during the annual conference of Magyar Angiológiai és Érsebészeti Társaság (Hungary, Balatonfüred, 2022. 05. 11-13.)

    2.    Vogl TJ. Potential Benefits of DVA in Prostatic Artery Embolisation. Oral presentation at Kinepict Symposium during CIRSE 2022 (Spain, Barcelona, 2022.09.13.)

    3.    Alizadeh L. Applications of Digital Variance Angiography and color-coded Digital Variance Angiography in Prostatic Artery Embolization. ECR 2022 (Austria, Vienna, 2022. 07.14.)

    4.    Alizadeh L. et al. Application and potential benefits of color-coded Digital Variance Angiography in Prostatic Artery Embolization. Poster presentation at RSNA 2022 (U.S., Chicago, 2022.11.27-12.01.)

    2020-1.1.5-GYORSÍTÓSÁV-2021-00018 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the 2020-1.1.5-GYORSÍTÓSÁV funding scheme.

     

  • European Innovation Council Summit 2022

    European Innovation Council Summit 2022

    The EIC Summit took place on 7-8 December 2022 in Brussels. The key European deep-tech innovation event of the year, was bringing together start-ups, researchers, investors, policy makers and corporates. Krisztián Szigeti represented Kinepict at the event.

  • CIRSE 2022 Kinepict Symposium

    CIRSE 2022 Kinepict Symposium

    The Kinepict Satellite Symposium was organized with the support of the EIC-Accelerator grant at CIRSE 2022. The program included the presentation of 5 outstanding clinicians using Kinepict’s technology. The presentations are available in CIRSE Library online.


  • The color-coded DVA Analysis Tool is available for clinical testing

    The color-coded DVA Analysis Tool is available for clinical testing

    The first milestone of the Gyorsítósáv project was reached in December 2021. The Kinepict Medical Imaging Tool with the ccDVA Analysis Tool software module is ready to be clinically tested.

    2020-1.1.5-GYORSÍTÓSÁV-2021-00018 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the 2020-1.1.5-GYORSÍTÓSÁV funding scheme.

  • The significance of the EIC accelerator grant in the present and future of Kinepict Health Ltd. at nyeromagyarok.hu

    The significance of the EIC accelerator grant in the present and future of Kinepict Health Ltd. at nyeromagyarok.hu

    The Hungarian Development Center covered Kinepict’s story in an interview with the founders of the company Dr. Krisztián Szigeti and Dr. Szabolcs Osváth. Read the full article HERE.

    https://nyeromagyarok.eu/

  • Substantial X-ray dose reduction capability of Kinepict Medical Imaging Tool is approved by the FDA

    Substantial X-ray dose reduction capability of Kinepict Medical Imaging Tool is approved by the FDA

    Substantial x-ray dose reduction capability of the Kinepict Medical Imaging Tool is reviewed and approved by U.S. Food and Drug Administration (FDA) during a 510(k) premarket notification procedure. Link to the record in the FDA database: click here!

  • Dose management capabilities of Digital Variance Angiography: 70% decrease of DSA-related radiation exposure in lower limb X-ray angiography

    Dose management capabilities of Digital Variance Angiography: 70% decrease of DSA-related radiation exposure in lower limb X-ray angiography

    Our colleague, Dr. Péter Legeza presented the scientific results of Kinepict Health Ltd. at the conference of the Hungarian Medical Association of America in Balatonfüred. The abstract of the presentation is available HERE.